Navigation Links
Poniard Pharmaceuticals to Host Third Quarter 2008 Financial Results Conference Call on October 30
Date:10/23/2008

SOUTH SAN FRANCISCO, Calif., Oct. 23 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that it will hold a conference call to discuss the Company's third quarter results and provide a corporate update, including an update on the ongoing development activities for picoplatin, the Company's lead product candidate.

Jerry McMahon, Ph.D., chairman and chief executive officer, Ronald A. Martell, president and chief operating officer, Caroline Loewy, chief financial officer, and Robert De Jager, M.D., FACP, chief medical officer, will host the call beginning at 5:00 p.m. Eastern time (2:00 p.m. Pacific time) on Thursday, October 30. A press release for the third quarter ended September 30, 2008, will be released after markets close on October 30.

To participate in the live call by telephone, please dial 877-419-6593 from the U.S. or 1-719-325-4885 for international callers. In addition, the live conference call is being webcast and can be accessed on the "Events" page of the "News & Events" section of the Company's website at http://www.poniard.com. A replay of the webcast will be available on the Company's website for 10 days.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum therapy with an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
2. Poniard Pharmaceuticals Announces Upgrade of Stock Listing to NASDAQ Global Market
3. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
5. Poniard Pharmaceuticals Announces Upcoming Conference Participation
6. Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update
7. Poniard Pharmaceuticals Appoints Four New Members to Clinical Advisory Board
8. Poniard Pharmaceuticals to Host Second Quarter 2008 Financial Results Conference Call on July 31
9. Poniard Pharmaceuticals Announces Upcoming Conference Participation
10. Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
11. Poniard Pharmaceuticals Announces Upcoming Conference Participation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 2013 was a ... Brain State Technologies®. They saw continued independent research led ... who were awarded a $1 million grant from the ... “Brain and Behavior” a peer reviewed journal, Amy Grant ...
(Date:1/15/2014)... 2014 TaiGen Biotechnology Company, Limited ("TaiGen") today announced ... a leading Russian pharmaceutical company, to develop and commercialize ... Federation , Turkey and ... a novel antibiotic for the treatment of bacterial infections ...
(Date:1/14/2014)... 14, 2014 Histogen, Inc., a regenerative ... cells grown under simulated embryonic conditions, today announced that ... Suneva Medical, Inc. for physician-dispensed aesthetic products containing Histogen’s ... This agreement is an amendment to the existing license ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 EquitiesIQ, a ... Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical company ... the wound care market. , Free report download: ... with a seasoned management team and Board, which launched ...
Breaking Biology Technology:Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... Genome Sciences at the University of Maryland School of ... Medical Research Institute of Infectious Diseases and Northern Arizona ... their investigation into the anthrax attacks of 2001. The ... microbiology in a criminal investigation. More than 20 people ...
... package designed to minimize the potential risks of synthetic ... available to the gene synthesis industry and synthetic biology ... licensed GenoTHREAT, a software tool that helps detect the ... an open-source project by a team led by Jean ...
... new drug that will regenerate a critical enzyme in ... exposed to deadly chemical warfare agents. Christopher Hadad, ... (OSU), is leveraging Ohio Supercomputer Center (OSC) resources to ... called organophosphorus (OP) nerve agents. "This project ...
Cached Biology Technology:University of Maryland School of Medicine publishes scientific paper on 2001 anthrax attacks 2University of Maryland School of Medicine publishes scientific paper on 2001 anthrax attacks 3University of Maryland School of Medicine publishes scientific paper on 2001 anthrax attacks 4Open-source software designed to minimize synthetic biology risks 2OSU chemist developing solution to nerve agent exposure 2
(Date:4/21/2014)... daily pill to lower cholesterol can reduce heart attack ... inflammation could help save the vision of diabetics, scientists ... with high doses of niacin to decrease bad cholesterol ... an effective mark for these patients, said Dr. Pamela ... Georgia Regents University. , Martin is Principal Investigator ...
(Date:4/21/2014)... In recent years, there are growing studies ... for sustained-release and controlled-release of nerve growth ... by Prof. Gao Li and team from ... and Technology in China, amino-functionalized ethylenediamine-treated multi-walled ... nanotubes-nerve growth factor complexes by non-covalent grafting. ...
(Date:4/20/2014)... to treat lung, breast and pancreatic cancers also promote ... University of California, San Diego School of Medicine have ... surface of drug-resistant tumors that appears responsible for inducing ... cancer cells. , The findings, published in the ... Biology , may point to new therapeutic opportunities for ...
Breaking Biology News(10 mins):Scientists target receptor to treat diabetic retinopathy 2Scientists target receptor to treat diabetic retinopathy 3Cancer stem cells linked to drug resistance 2
... Jewish Health have discovered a type of cell that may ... lupus, multiple sclerosis and rheumatoid arthritis strike women more frequently ... make autoantibodies, which bind to and attack the body,s own ... of the journal Blood , that they found higher ...
... programmed cell death - a process by which cells ... in termites. And it appears this regression may be ... defensive organs, according to Kouhei Toga and Kiyoto Maekawa ... the University of Tokyo, in Japan. Their findings have ...
... tropics make it tough for farmers to keep their crops ... seems to defy efforts to control its population. Some farmers ... the weevils but they have not been successful. Since the ... the immature stages. The sweetpotato weevil is a year round ...
Cached Biology News:B-cell discovery suggests why women suffer more autoimmune disease 2Cells die so defensive organs can live 2Biocontrol of sweetpotato weevils 2
...
... Antibody Modification Services ,,GenScript ... antibody labeling and antibody fragmentation. Labeling ... signals for visualization and quantitation of ... it is preferable to use only ...
Attoglow Western Blot Enhancing Kit contains Millennium Enhancer which can significantly boost Western blot signals, and is compatible with other enhancing mechanisms to achieve multiplied enhancing ...
Immunogen: Synthetic peptide: S(399) P W S E L E F Q F P D D K D P V W E F(418) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: